Aurintricarboxylic Acid Attenuates Tramadol Withdrawal Syndrome Via TWEAK/FN14 Inhibition and CREB Modulation in Mice Model
NeuroMolecular Medicine · 2025
DOI: 10.1007/s12017-025-08893-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift NeuroMolecular Medicine, 2025. Verfasst von Rajalaxmi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Chitkara College of Pharmacy, Chitkara University, Punjab, India. Hauptthemen laut MEDLINE: Cyclic AMP Response Element-Binding Protein, Tramadol, Substance Withdrawal Syndrome, Cytokine TWEAK. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 57 Literaturangaben.
Abstract (Originalsprache)
Tramadol withdrawal presents a significant clinical challenge, characterized by neurobehavioral impairments linked to neuroinflammation, oxidative stress and neurotransmitter dysregulation. The TNF-like weak inducer of apoptosis (TWEAK)/fibroblast growth factor-inducer 14 (Fn14) pathway and downstream effectors like cAMP response element binding protein (CREB) are implicated, but effective targeted therapies are lacking. Aurintricarboxylic acid (ATA), a TWEAK inhibitor, exhibits neuroprotective potential. This study aims to evaluate the therapeutic efficacy of ATA in mitigating the tramadol withdrawal-induced neurobehavioral alterations in mice model, focusing on the role of TWEAK/Fn14 pathway and CREB phosphorylation. Swiss albino mice were subjected to chronic tramadol administration (50 mg/kg, s.c.) for 57 days, with withdrawal precipitated with naloxone (5 mg/kg, i.p.) on day 57. Behavioural assessments included withdrawal severity score (WSS), jumping frequency, and hyperalgesia. Biochemical analyses measured the level of oxidative stress markers (TBARS, SOD, GSH and catalase), inflammatory biomarkers (TNF-α, IL-6, IL-1β), and neurotransmitters (glutamate, dopamine and serotonin). ATA (5 mg/kg and 10 mg/kg i.p.) dose-dependently reduced the WSS, jumping frequency and hyperalgesia. It also mitigated the oxidative stress, neuroinflammation, and glutamate level, while restoring the neurotransmitter level. Notably, pretreatment with CREB inhibitor (666 - 15) (10 mg/kg i.p) significantly attenuated the protective effect of ATA, underscoring the pivotal role of CREB phosphorylation in its mechanism. Our findings demonstrate that ATA offers significant neuroprotection against tramadol withdrawal, primarily by inhibiting the TWEAK/Fn14 pathway and subsequently promoting the CREB phosphorylation. This study highlights ATA as a promising therapeutic candidate for managing tramadol withdrawal syndrome by targeting oxidative stress, neuroinflammation, and its downstream effectors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chitkara College of Pharmacy, Chitkara University, Punjab, India.
- Chitkara College of Pharmacy, Chitkara University, Punjab, India. amarjot.kaur@chitkara.edu.in.
- Department of Pharmaceutical Sciences and Technology, Maharaja Ranjit Singh Punjab Technical University, Bathinda, Punjab, India. varinderjassal17@gmail.com.
Zitieren
APA
Rajalaxmi, Wani, S. N., Grewal, A. K., Singh, V., Kumar, A., Khan, H., & Singh, T. G. (2025). Aurintricarboxylic Acid Attenuates Tramadol Withdrawal Syndrome Via TWEAK/FN14 Inhibition and CREB Modulation in Mice Model. NeuroMolecular Medicine. https://doi.org/10.1007/s12017-025-08893-7
Vancouver
Rajalaxmi, Wani SN, Grewal AK, Singh V, Kumar A, Khan H, et al. Aurintricarboxylic Acid Attenuates Tramadol Withdrawal Syndrome Via TWEAK/FN14 Inhibition and CREB Modulation in Mice Model. NeuroMolecular Medicine. 2025. doi:10.1007/s12017-025-08893-7
BibTeX
@article{Rajalaxmi2025,
author = {Rajalaxmi and Wani, Shahid Nazir and Grewal, Amarjot Kaur and Singh, Varinder and Kumar, Amit and Khan, Heena and Singh, Thakur Gurjeet},
title = {Aurintricarboxylic Acid Attenuates Tramadol Withdrawal Syndrome Via TWEAK/FN14 Inhibition and CREB Modulation in Mice Model},
journal = {NeuroMolecular Medicine},
year = {2025},
doi = {10.1007/s12017-025-08893-7}
}
EUVIMED